Biotech investors may be missing out on some very lucrative drugs and therapies. As today’s article notes, while “It is common for large-cap biotech investments…to feature exposure to companies working on treatments for well-known diseases…the growing unmet medical needs universe is going, well, mostly unmet by traditional biotech investments.” Case in point: Non-alcoholic steatohepatitis (NASH) – a potentially fatal liver disease affecting upwards of 16 million Americans and for which there is currently no approved drug therapy. So how can biotech investors access the opportunity presented by NASH and other unmet medical needs? CLICK HERE.